Isabelle Pellegrin
Department of Virology
Bordeaux University Hospital
Bordeaux
France
Name/email consistency: high
- Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Pellegrin, I., Wittkop, L., Joubert, L.M., Neau, D., Bollens, D., Bonarek, M., Girard, P.M., Fleury, H., Winters, B., Saux, M.C., Pellegrin, J.L., Thiébaut, R., Breilh, D. Antivir. Ther. (Lond.) (2008)
- Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Pellegrin, I., Breilh, D., Coureau, G., Boucher, S., Neau, D., Merel, P., Lacoste, D., Fleury, H., Saux, M.C., Pellegrin, J.L., Lazaro, E., Dabis, F., Thiébaut, R. Antimicrob. Agents Chemother. (2007)
- Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Pellegrin, I., Breilh, D., Ragnaud, J.M., Boucher, S., Neau, D., Fleury, H., Schrive, M.H., Saux, M.C., Pellegrin, J.L., Lazaro, E., Vray, M. Antivir. Ther. (Lond.) (2006)
- Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. Pellegrin, I., Thiébaut, R., Blanco, P., Viallard, J.F., Schrive, M.H., Merel, P., Chêne, G., Fleury, H., Moreau, J.F., Pellegrin, J.L. J. Med. Virol. (2005)
- Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. Pellegrin, I., Caumont, A., Garrigue, I., Merel, P., Schrive, M.H., Fleury, H., Dupon, M., Pellegrin, J.L., Ragnaud, J.M. J. Infect. Dis. (2003)
- New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. Pellegrin, I., Garrigue, I., Ekouevi, D., Couzi, L., Merville, P., Merel, P., Chene, G., Schrive, M.H., Trimoulet, P., Lafon, M.E., Fleury, H. J. Infect. Dis. (2000)
